top of page

2024

2023

Rhéaume K#, Chen Z#, Wang Y#, Plante C, Hewa Bostanthirige D, Lévesque M, Geha S, Le LQ and Brosseau JP$ (2023). Whole central and peripheral nervous system mice dissection. Journal of Visualized Experiments. (192), e64974

2021

Mohamad T, Plante C, and Brosseau JP$ (2021). Toward understanding the mechanism of malignant peripheral nerve sheath tumor. International Journal of Molecular Sciences. 22(16) :8620

Brosseau JP$#, Sathe AA#, Wang Y, Nguyen T, Glass DA, Xing C, and Le LQ$. Human Cutaneous Neurofibroma Matrisome Revealed by SingleCell RNA Sequencing. Acta Neuropathologica Communications. 2021 9(1)

Yao H, Li C, He F, Song T, Brosseau JP, Wang H, Lu H, Fang C, Shi H, Lan J Zhang Y, Fang JY and Xu J. (2021). A peptidic inhibitor for PD-1 palmitoylation targets its expression and functions. RSC Chemical Biology. 2(1):192-205

2020

Brosseau JP. (2020). Regulations on messenger RNA: wires and nodes. Advances in Experimental Medicine and Biology. 1248: 251-264

Xu J, Brosseau JP and Shi H. (2020). Targeted degradation of immune checkpoint proteins: emerging strategies for cancer immunotherapy. Oncogene 39(48):7106-7113

Chen Z, Li S, Mo J, Hawley E, Wang Y, He Y, Brosseau JP, Shipman T, Clapp DW, Carroll TJ, Le LQ. Schwannoma Development is Mediated by Hippo Pathway Dysregulation and Modified by RAS/MAPK Signaling. JCI Insight. 2020 5(20)

Brosseau JP$, Liao CP and Le LQ$. Translating current basic research into future therapies for Neurofibromatosis type I. British Journal of Cancer. 2020 123: 178-87

2019

Brosseau JP$ and Le LQ$. Heterozygous Tumor Suppressor Microenvironment in Cancer Development. Trends in Cancer 2019(9):541-6

Yao H, Lan J, Li C, Shi H, Brosseau JP, Wang H, Lu H, Fang C, Zhang Y, Liang L, Zhou X, Wang C, Xue Y, Cui Y and Xu J. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumors. Nature Biomedical Engineering 2019;3(4):306-17

Chen Z, Mo J, Brosseau JP, Shipman T, Wang Y, Liao CP, Allaway RJ, Gosline SJC, Guinney J and Le LQ. Spatiotemporal Loss of NF1 in Schwann Cell Lineage Leads to Different Types of Cutaneous Neurofibroma Susceptible to Modification by the Hippo Pathway. Cancer Discovery 2019;9(1):114-29

2018

Brosseau JP. Splicing Isoform-Specific Functional Genomic in cancer cells. Applied Cancer Research 2018;38:18

Brosseau JP, Liao CP, Wang Y, Ramani V, Vandergriff T, Lee M*, Patel A*, Ariizumi K and Le LQ. NF1 Heterozygosity Fosters de Novo Tumorigenesis, but Impairs Malignant Transformation. Nature Communications 2018;9(1):5014

Liao CP, Booker R, Brosseau JP, Chen Z, Mo J, Tchegnon E, Wang Y, Clapp W, and Le LQ. Contribution of Inflammation and Tumor Microenvironment to Neurofibroma Tumorigenesis. Journal of Clinical Investigation 2018;128(7):2848-61

Brosseau JP#, Pichard DC#, Legius E, Wolkenstein P, Lavker RM, Blakeley JO, Riccardi VM, Verma S, Brownell I, and Le LQ. The Biology of Cutaneous Neurofibroma. Neurology 2018;91(Suppl 1):S14-20

2014

Brosseau JP, Lucier JF, Lamarche AA, Shkreta L, Gendron D, Lapointe E, Thibault P, Paquet E, Perreault JP, Elela SA, and Chabot B. Redirecting Splicing With Interfering and Stimulating Bifunctional Oligonucleotides. Nucleic Acids Research 2014;42(6):e40

Brosseau JP, Lucier JF, Nwilati H, Thibault P, Garneau D, Gendron D, Durand M, Couture S, Lapointe E, Prinos P, Klinck R, Chabot B, Perreault JP, and Elela SA. Tumor Microenvironment Associated Modifications of Alternative Splicing RNA 2014;20(2):189-201

2013

Lecka J, Gillerman I, Fausther M, Salem M, Munkonda MN, Brosseau JP, Cadot C, Martín-Satué M, d'Orléans-Juste P, Rousseau E, Poirier D, Künzli B, Fischer B, Sévigny J. 8-BuS-ATP Derivatives as Specific NTPDase1 Inhibitors. British Journal of Pharmacology 2013;169(1):179-96

Venables JP, Brosseau JP, Gadea G, Klinck R, Prinos P, Beaulieu JF, Lapointe E, Durand M, Thibault P, Tremblay K, Rousset F, Tazi J, Elela SA, and Chabot B. RBFOX2 Enforces the Mesenchymal Splicing Signature in Normal and Cancer Tissues. Molecular and Cellular Biology 2013;33(2):396-405

bottom of page